Boston Private Wealth LLC reduced its position in shares of Colgate-Palmolive (NYSE:CL) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,914 shares of the company’s stock after selling 4,861 shares during the quarter. Boston Private Wealth LLC’s holdings in Colgate-Palmolive were worth $9,974,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Harding Loevner LP raised its position in Colgate-Palmolive by 92.0% during the third quarter. Harding Loevner LP now owns 4,742,752 shares of the company’s stock worth $176,329,000 after acquiring an additional 2,272,675 shares in the last quarter. USS Investment Management Ltd raised its position in Colgate-Palmolive by 1.9% during the third quarter. USS Investment Management Ltd now owns 696,700 shares of the company’s stock worth $50,737,000 after acquiring an additional 13,100 shares in the last quarter. Tiedemann Wealth Management LLC increased its holdings in shares of Colgate-Palmolive by 38.5% in the third quarter. Tiedemann Wealth Management LLC now owns 15,608 shares of the company’s stock valued at $929,000 after purchasing an additional 4,336 shares during the last quarter. Crystal Rock Capital Management acquired a new position in shares of Colgate-Palmolive in the third quarter valued at $2,003,000. Finally, Commonwealth Bank of Australia increased its holdings in shares of Colgate-Palmolive by 11.8% in the third quarter. Commonwealth Bank of Australia now owns 634,577 shares of the company’s stock valued at $45,997,000 after purchasing an additional 67,213 shares during the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Jennifer Daniels sold 902 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $75.82, for a total transaction of $68,389.64. Following the completion of the sale, the insider now owns 37,788 shares of the company’s stock, valued at $2,865,086.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stephen I. Sadove sold 20,780 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $70.52, for a total transaction of $1,465,405.60. Following the sale, the director now directly owns 36,268 shares of the company’s stock, valued at approximately $2,557,619.36. The disclosure for this sale can be found here. Insiders sold 181,950 shares of company stock worth $13,237,385 over the last 90 days. 1.02% of the stock is currently owned by corporate insiders.
Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, October 27th. The company reported $0.73 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.73. Colgate-Palmolive had a net margin of 15.10% and a return on equity of 2,782.56%. The business had revenue of $3.97 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same period in the prior year, the company posted $0.73 earnings per share. Colgate-Palmolive’s revenue was up 2.8% compared to the same quarter last year. research analysts anticipate that Colgate-Palmolive will post 2.88 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Tuesday, January 23rd will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.14%. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 61.78%.
Several equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $84.00 price objective on the stock in a report on Monday, January 8th. Macquarie upgraded shares of Colgate-Palmolive from a “neutral” rating to an “outperform” rating and set a $81.00 price objective on the stock in a report on Tuesday, December 19th. Deutsche Bank assumed coverage on shares of Colgate-Palmolive in a report on Wednesday, December 13th. They issued a “hold” rating and a $75.00 price objective on the stock. Societe Generale downgraded shares of Colgate-Palmolive from a “hold” rating to a “sell” rating and set a $66.00 price objective on the stock. in a report on Wednesday, November 29th. They noted that the move was a valuation call. Finally, KeyCorp reiterated a “hold” rating on shares of Colgate-Palmolive in a report on Saturday, November 25th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $76.51.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.